Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

NCT03579966 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

63

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of measure appropriate data (MG-ADL).

Conditions

Myasthenia Gravis, MuSK
AChR Myasthenia Gravis

Interventions

DRUG: Amifampridine Phosphate

Sponsor

Catalyst Pharmaceuticals, Inc.